Vaccine Technologies and Platforms for Infectious Diseases: Current Progress, Challenges, and Opportunities

Vaccines (Basel). 2021 Dec 16;9(12):1490. doi: 10.3390/vaccines9121490.

Abstract

Vaccination is a key component of public health policy with demonstrated cost-effective benefits in protecting both human and animal populations. Vaccines can be manufactured under multiple forms including, inactivated (killed), toxoid, live attenuated, Virus-like Particles, synthetic peptide, polysaccharide, polysaccharide conjugate (glycoconjugate), viral vectored (vector-based), nucleic acids (DNA and mRNA) and bacterial vector/synthetic antigen presenting cells. Several processes are used in the manufacturing of vaccines and recent developments in medical/biomedical engineering, biology, immunology, and vaccinology have led to the emergence of innovative nucleic acid vaccines, a novel category added to conventional and subunit vaccines. In this review, we have summarized recent advances in vaccine technologies and platforms focusing on their mechanisms of action, advantages, and possible drawbacks.

Keywords: DNA vaccine; Virus-like Particles; inactivated vaccine; live attenuated vaccine; mRNA vaccine; next generation vaccines; polysaccharide vaccine; toxoid vaccine; vaccine; vaccine platforms; vaccine types; viral vectored vaccine.

Publication types

  • Review